



# MINNESOTA BOARD OF PHARMACY

## Report to the Legislature on the Minnesota Insulin Safety Net Program. (In compliance with Minnesota Statutes Section 151.74, Subd. 13)

*Jill Phillips MPH, R.Ph.*

*Executive Director  
Minnesota Board of  
Pharmacy*

*335 Randolph Ave, #230  
St. Paul, MN 55102*

*(651)201-2825*

*[jill.phillips@state.mn.us](mailto:jill.phillips@state.mn.us)*

March 1, 2024

## **COST OF REPORT**

Minnesota Statutes §3.197 states that a “report to the legislature must contain, at the beginning of the report, the cost of preparing the report, including any costs incurred by another agency or another level of government”. The estimated cost of preparing this report was **\$400.00**. That is the approximate value, in terms of salary and benefits, of the time that Board staff spent preparing the report.

(The rest of this page is intentionally blank).

## Introduction

The Board of Pharmacy (Board) is submitting this report to the Legislature in compliance with Minn. Stats. §151.74, subdivision 13, which states:

Subd. 13. **Reports.** (a) By February 15 of each year, beginning February 15, 2021, each manufacturer shall report to the Board of Pharmacy the following:

1. (1) the number of Minnesota residents who accessed and received insulin on an urgent-need basis under this section in the preceding calendar year;
2. (2) the number of Minnesota residents participating in the manufacturer's patient assistance program in the preceding calendar year, including the number of Minnesota residents who the manufacturer determined were ineligible for their patient assistance program; and
3. the value of the insulin provided by the manufacturer under clauses (1) and (2).

For purposes of this paragraph, "value" means the wholesale acquisition cost of the insulin provided.

(b) By March 15 of each year, beginning March 15, 2021, the Board of Pharmacy shall submit the information reported in paragraph (a) to the chairs and ranking minority members of the legislative committees with jurisdiction over health and human services policy and finance. The board shall also include in the report any administrative penalties assessed under subdivision 10, including the name of the manufacturer and amount of the penalty assessed.

## Reporting By Manufacturers

The five manufacturers participating in the Minnesota Insulin Safety Net Program are Eli Lilly and Company, Sanofi, Novo Nordisk, Mylan Specialty LP., a Viatris company and Biocon Biologics. All five manufacturers submitted the required data for calendar year 2023 by the February 15, 2024 deadline. The data and other information reported are provided below.

The data submitted indicates that, collectively, the five manufacturers provided insulin under the Minnesota Insulin Safety Net Program to as many as **269 residents**. Since some residents may have received insulin under both the Urgent and Continuing Needs Programs, fewer total residents may have benefited. The total value of the insulin received by residents was **\$152,802.11**. (Based on the wholesale acquisition cost of the insulin – not the cost that the residents would have paid if they had purchased the insulin on their own).

**Eli Lilly**

Urgent Need Recipients	104
Value of Insulin Provided to Urgent Need Recipients	\$45,992.38
Continuing Need Applicants	
Total number of participants	6
Total number of ineligible applicants	1
Value of Insulin Provided to Continuing Need Recipients	\$10,180.15
Total Value of Insulin Provided	\$56,172.53

The report reflects participation in Lilly’s Minnesota patient assistance programs only. Lilly offers a number of other insulin affordability solutions for patients. Minnesota residents may have accessed Lilly insulin through Lilly’s other assistance programs, and these patients (and the value of the associated insulin) are not included in this report. Note a patient may have applied to the continuing care program to receive more than one product or used the urgent needs program for more than one product. In those cases, the patient is counted only one time in the respective program.

The “Total number of participants” in the Lilly MN Continuing Needs Program reflects the number of unique patients who received product in 2023. This includes individuals who may have enrolled in 2022, but who continued to receive product in 2023 (when their enrollment expired), as well as new patients who enrolled in the program and received product in 2023.

Value of Insulin Provided is the WAC price of the product on the date filled by the patient.

**Novo Nordisk**

Novo Nordisk provided the following data:

Urgent Need Recipients	33
Value of Insulin Provided to Urgent Need Recipients	\$21,504.40
Continuing Need Applicants	
Total number of participants	5
Total number of ineligible applicants	7
Value of Insulin Provided to Continuing Need Recipients	\$22,822
Total Value of Insulin Provided	44,326.40

## **Sanofi**

Sanofi provided the following submission notes:

WAC = Wholesale Acquisition Cost

The below figures are reflective of the Minnesota mandated programs that Sanofi offers only and do not include data for any other Sanofi run programs

\*The "manufacturer's patient assistance program" in Clause 2 below is only referring to the Minnesota mandated program that Sanofi offers

\*\*The "Total number of participants" in Clause 2 below means the total number of Minnesota residents that received at least 1 shipment of product in calendar year 2023

Sanofi provided the following data:

Urgent Need Recipients	106
Value of Insulin Provided to Urgent Need Recipients	\$48,794
Continuing Need Applicants* (Clause 2)	
Total number of applicants	11
Total number of ineligible applicants	0
Value of Insulin Provided to Continuing Need Recipients	\$2,149.08
Total Value of Insulin Provided	\$50,943.08

## **Viatrix (Mylan)**

Viatrix provided the following submission notes:

Number of MN residents participating in patient assistance programs (PAP)*	1
Total number of applicants	1
Total number of ineligible applicants	0
Value of Insulin Provided to PAP patients	\$1,616.28
Urgent Needs Recipients	0
Number of MN residents participating in MN Continuing Need Program*	2
Total number of applicants	20
Total number of ineligible applicants	N/A
Value of Insulin Provided to Continuing Need Recipients	\$552.02
Total Value of Insulin Provided in MN	\$2,168.30

\*Note: All Minnesota patients are reviewed under Viatrix' current free drug PAP eligibility criteria; however, if a patient from Minnesota does not qualify for free drug under our PAP, then that patient would be immediately re-evaluated under our Minnesota Insulin Continuing Need (Safety Net) Program eligibility criteria.

**Biocon Biologics**

As of September 1, 2023, Biocon Biologics Inc. assumed the marketing of insulin products in Minnesota from Mylan Specialty L.P., a Viatris company. Pursuant to Minn. Stat. 151.74 (2020) (the "Act"), please see below for required annual reporting on the following: (1) the number of Minnesota residents who accessed and received insulin on an urgent-need basis under this section in the preceding calendar year; (2) the number of Minnesota residents participating in the manufacturer's patient assistance program in the preceding calendar year, including the number of Minnesota residents who the manufacturer determined were ineligible for their patient assistance program; and (3) the value of the insulin provided by the manufacturer under clauses (1) and (2).

Urgent Need Recipients	2
Value of Insulin Provided to Urgent Need Recipients	\$808.08
Number of MN residents participating in patient assistance programs (PAP)*	0
Total number of applicants	0
Total number of ineligible applicants	0
Value of Insulin Provided to PAP patients	\$0

**Assessment of Civil Penalties**

The five insulin manufacturers complied with the provisions of Minn. Stats. §151.74. Consequently, the Board did not assess any civil penalties under subdivision 10.